{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:53:05Z","timestamp":1787064785927,"version":"build-2736575974"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003802","name":"University Research Committee, University of Hong Kong","doi-asserted-by":"publisher","award":["104006626"],"award-info":[{"award-number":["104006626"]}],"id":[{"id":"10.13039\/501100003802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1515120035, 2024A1515012035"],"award-info":[{"award-number":["2023B1515120035, 2024A1515012035"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2020A0505100045"],"award-info":[{"award-number":["2020A0505100045"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007156","name":"Innovation and Technology Commission - Hong Kong","doi-asserted-by":"publisher","award":["Health@InnoHK programme"],"award-info":[{"award-number":["Health@InnoHK programme"]}],"id":[{"id":"10.13039\/501100007156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ischemic stroke is one of the major diseases causing varying degrees of dysfunction and disability worldwide. The current management of ischemic stroke poses significant challenges due to short therapeutic windows and limited efficacy, highlighting the pressing need for novel neuroprotective treatment strategies. Previous studies have shown that fingolimod (FIN) is a promising neuroprotective drug. Here, we report the rational development of FIN nano-embedded nasal powders using full factorial design experiments, aiming to provide rapid neuroprotection after ischemic stroke. Flash nanoprecipitation was employed to produce FIN nanosuspensions with the aid of polyvinylpyrrolidone and cholesterol as stabilizers. The optimized nanosuspension (particle size\u2009=\u2009134.0\u2009\u00b1\u20090.6\u00a0nm, PDI\u2009=\u20090.179\u2009\u00b1\u20090.021, physical stability\u2009=\u200972\u2009\u00b1\u20090\u00a0h, and encapsulation efficiency of FIN\u2009=\u200990.67\u2009\u00b1\u20090.08%) was subsequently spray-dried into a dry powder, which exhibited excellent redispersibility (RdI\u2009=\u20091.09\u2009\u00b1\u20090.04) and satisfactory drug deposition in the olfactory region using a customized 3D-printed nasal cast (45.4%) and an Alberta Idealized Nasal Inlet model (8.6%) at 15\u00a0L\/min. The safety of the optimized FIN nano-embedded dry powder was confirmed in cytotoxicity studies with nasal (RPMI 2650 and Calu-3 cells) and brain related cells (SH-SY5Y and PC 12 cells), while the neuroprotective effects were demonstrated by observed behavioral improvements and reduced cerebral infarct size in a middle cerebral artery occlusion mouse stroke model. The neuroprotective effect was further evidenced by increased expression of anti-apoptotic protein BCL-2 and decreased expression of pro-apoptotic proteins CC3 and BAX in brain peri-infarct tissues. Our findings highlight the potential of nasal delivery of FIN nano-embedded dry powder as a rapid neuroprotective treatment strategy for acute ischemic stroke.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-024-01721-8","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T08:04:35Z","timestamp":1730448275000},"page":"2022-2047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rational development of fingolimod nano-embedded microparticles as nose-to-brain neuroprotective therapy for ischemic stroke"],"prefix":"10.1007","volume":"15","author":[{"given":"Xinyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangpu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Wan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Kwan","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4588-5346","authenticated-orcid":false,"given":"Shing Fung","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"2","key":"1721_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/s-0038-1649503","volume":"38","author":"M Katan","year":"2018","unstructured":"Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018;38(2):208\u201311.","journal-title":"Semin Neurol"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"115251","DOI":"10.1016\/j.ejmech.2023.115251","volume":"251","author":"Y-L Chen","year":"2023","unstructured":"Chen Y-L, et al. Discovery of phenylcarbamoyl xanthone derivatives as potent neuroprotective agents for treating ischemic stroke. Eur J Med Chem. 2023;251:115251.","journal-title":"Eur J Med Chem"},{"issue":"9","key":"1721_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2174\/1570159X16666180302115544","volume":"16","author":"E Sekerdag","year":"2018","unstructured":"Sekerdag E, Solaroglu I, Gursoy-Ozdemir Y. Cell death mechanisms in Stroke and Novel Molecular and Cellular Treatment options. Curr Neuropharmacol. 2018;16(9):1396\u2013415.","journal-title":"Curr Neuropharmacol"},{"key":"1721_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejpb.2023.06.015","volume":"189","author":"CYJ Wong","year":"2023","unstructured":"Wong CYJ, et al. Engineered dry powders for the nose-to-brain delivery of transforming growth factor-beta. Eur J Pharm Biopharm. 2023;189:202\u201311.","journal-title":"Eur J Pharm Biopharm"},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"101631","DOI":"10.1016\/j.apmt.2022.101631","volume":"29","author":"ML Formica","year":"2022","unstructured":"Formica ML, et al. On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022;29:101631.","journal-title":"Appl Mater Today"},{"issue":"2","key":"1721_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","volume":"151","author":"Z Wen","year":"2011","unstructured":"Wen Z, et al. Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration. J Control Release. 2011;151(2):131\u20138.","journal-title":"J Control Release"},{"key":"1721_CR7","doi-asserted-by":"crossref","unstructured":"Lee D, Minko T. Nanotherapeutics for nose-to-Brain Drug Delivery: an Approach to bypass the blood brain barrier. Pharmaceutics, 2021. 13(12).","DOI":"10.3390\/pharmaceutics13122049"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"119243","DOI":"10.1016\/j.ijpharm.2020.119243","volume":"580","author":"E Touitou","year":"2020","unstructured":"Touitou E, Duchi S, Natsheh H. A new nanovesicular system for nasal drug administration. Int J Pharm. 2020;580:119243.","journal-title":"Int J Pharm"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"110446","DOI":"10.1016\/j.colsurfb.2019.110446","volume":"183","author":"W Du","year":"2019","unstructured":"Du W, et al. Development of nose-to-brain delivery of ketoconazole by nanostructured lipid carriers against cryptococcal meningoencephalitis in mice. Colloids Surf B Biointerfaces. 2019;183:110446.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1721_CR10","first-page":"111236","volume":"116","author":"K Mohsen","year":"2020","unstructured":"Mohsen K, et al. Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: in vitro optimization and in vivo pharmacokinetic study. Biomater Adv. 2020;116:111236.","journal-title":"Biomater Adv"},{"key":"1721_CR11","doi-asserted-by":"crossref","unstructured":"Sonvico F et al. Surface-modified nanocarriers for nose-to-brain delivery: from Bioadhesion to Targeting. Pharmaceutics, 2018. 10(1).","DOI":"10.3390\/pharmaceutics10010034"},{"key":"1721_CR12","doi-asserted-by":"publisher","first-page":"122588","DOI":"10.1016\/j.ijpharm.2023.122588","volume":"632","author":"M Elhabak","year":"2023","unstructured":"Elhabak M, Salama AAA, Salama AH. Nose-to-brain delivery of galantamine loaded nanospray dried polyacrylic acid\/taurodeoxycholate mixed matrix as a protective therapy in lipopolysaccharide-induced Alzheimer\u2019s in mice model. Int J Pharm. 2023;632:122588.","journal-title":"Int J Pharm"},{"key":"1721_CR13","first-page":"363","volume":"6","author":"S Eskandari","year":"2011","unstructured":"Eskandari S, et al. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed. 2011;6:363\u201371.","journal-title":"Int J Nanomed"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"122038","DOI":"10.1016\/j.ijpharm.2022.122038","volume":"624","author":"M Perku\u0161i\u0107","year":"2022","unstructured":"Perku\u0161i\u0107 M, et al. Tailoring functional spray-dried powder platform for efficient donepezil nose-to-brain delivery. Int J Pharm. 2022;624:122038.","journal-title":"Int J Pharm"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejps.2017.09.027","volume":"113","author":"L Tiozzo Fasiolo","year":"2018","unstructured":"Tiozzo Fasiolo L, et al. Opportunity and challenges of nasal powders: drug formulation and delivery. Eur J Pharm Sci. 2018;113:2\u201317.","journal-title":"Eur J Pharm Sci"},{"key":"1721_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejpb.2018.06.011","volume":"129","author":"L Salade","year":"2018","unstructured":"Salade L, et al. Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery. Eur J Pharm Biopharm. 2018;129:257\u201366.","journal-title":"Eur J Pharm Biopharm"},{"key":"1721_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.carbpol.2017.01.044","volume":"163","author":"SB Yarragudi","year":"2017","unstructured":"Yarragudi SB, et al. Formulation of olfactory-targeted microparticles with tamarind seed polysaccharide to improve nose-to-brain transport of drugs. Carbohydr Polym. 2017;163:216\u201326.","journal-title":"Carbohydr Polym"},{"issue":"1","key":"1721_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/jamp.2013.1084","volume":"28","author":"JD Schroeter","year":"2014","unstructured":"Schroeter JD, et al. Experimental measurements and Computational Predictions of Regional Particle Deposition in a Sectional Nasal Model. J Aerosol Med Pulm Drug Deliv. 2014;28(1):20\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"1721_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jconrel.2004.08.001","volume":"100","author":"VM Leitner","year":"2004","unstructured":"Leitner VM, et al. Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer\/glutathione microparticulate delivery system. J Control Release. 2004;100(1):87\u201395.","journal-title":"J Control Release"},{"issue":"2","key":"1721_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11095-006-9146-7","volume":"24","author":"BY Shekunov","year":"2007","unstructured":"Shekunov BY, et al. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm Res. 2007;24(2):203\u201327.","journal-title":"Pharm Res"},{"issue":"1","key":"1721_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.004","volume":"67","author":"L Di Menna","year":"2013","unstructured":"Di Menna L, et al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res. 2013;67(1):1\u20139.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1721_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.22186","volume":"69","author":"Y Wei","year":"2011","unstructured":"Wei Y, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69(1):119\u201329.","journal-title":"Ann Neurol"},{"issue":"21","key":"1721_CR23","doi-asserted-by":"publisher","first-page":"e2311803","DOI":"10.1002\/adma.202311803","volume":"36","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, et al. Neutrophil membrane-camouflaged Polyprodrug Nanomedicine for inflammation suppression in ischemic stroke therapy. Adv Mater. 2024;36(21):e2311803.","journal-title":"Adv Mater"},{"issue":"51","key":"1721_CR24","doi-asserted-by":"publisher","first-page":"18315","DOI":"10.1073\/pnas.1416166111","volume":"111","author":"Y Fu","year":"2014","unstructured":"Fu Y, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 2014;111(51):18315\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"1721_CR25","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1021\/acschemneuro.1c00153","volume":"12","author":"L Subedi","year":"2021","unstructured":"Subedi L, Gaire BP. Neuroprotective effects of Curcumin in Cerebral Ischemia: Cellular and Molecular mechanisms. ACS Chem Neurosci. 2021;12(14):2562\u201372.","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"1721_CR26","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.ces.2007.10.020","volume":"63","author":"Y Liu","year":"2008","unstructured":"Liu Y, et al. Mixing in a multi-inlet vortex mixer (MIVM) for flash nano-precipitation. Chem Eng Sci. 2008;63(11):2829\u201342.","journal-title":"Chem Eng Sci"},{"issue":"1\u20132","key":"1721_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijpharm.2018.03.006","volume":"542","author":"KY Wan","year":"2018","unstructured":"Wan KY, et al. Impact of molecular rearrangement of amphiphilic stabilizers on physical stability of itraconazole nanoparticles prepared by flash nanoprecipitation. Int J Pharm. 2018;542(1\u20132):221\u201331.","journal-title":"Int J Pharm"},{"issue":"1","key":"1721_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/acs.molpharmaceut.8b00945","volume":"16","author":"KY Wan","year":"2019","unstructured":"Wan KY, et al. Interplay between Amphiphilic Stabilizers and cholesterol in the stabilization of Itraconazole nanoparticles prepared by Flash Nanoprecipitation. Mol Pharm. 2019;16(1):195\u2013204.","journal-title":"Mol Pharm"},{"issue":"2","key":"1721_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nantod.2016.04.006","volume":"11","author":"WS Saad","year":"2016","unstructured":"Saad WS, Prud\u2019homme RK. Principles of nanoparticle formation by flash nanoprecipitation. Nano Today. 2016;11(2):212\u201327.","journal-title":"Nano Today"},{"key":"1721_CR30","doi-asserted-by":"publisher","first-page":"120224","DOI":"10.1016\/j.ijpharm.2021.120224","volume":"598","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. Physical stability and in vivo brain delivery of polymeric ibuprofen nanoparticles fabricated by flash nanoprecipitation. Int J Pharm. 2021;598:120224.","journal-title":"Int J Pharm"},{"key":"1721_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ejpb.2015.06.022","volume":"94","author":"SF Chow","year":"2015","unstructured":"Chow SF, et al. Development of highly stabilized curcumin nanoparticles by flash nanoprecipitation and lyophilization. Eur J Pharm Biopharm. 2015;94:436\u201349.","journal-title":"Eur J Pharm Biopharm"},{"key":"1721_CR32","doi-asserted-by":"publisher","first-page":"123303","DOI":"10.1016\/j.ijpharm.2023.123303","volume":"644","author":"HW Chan","year":"2023","unstructured":"Chan HW, et al. Integrated continuous manufacturing of inhalable remdesivir nanoagglomerate dry powders: design, optimization and therapeutic potential for respiratory viral infections. Int J Pharm. 2023;644:123303.","journal-title":"Int J Pharm"},{"issue":"2","key":"1721_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejor.2008.02.018","volume":"195","author":"I-J Jeong","year":"2009","unstructured":"Jeong I-J, Kim K-J. An interactive desirability function method to multiresponse optimization. Eur J Oper Res. 2009;195(2):412\u201326.","journal-title":"Eur J Oper Res"},{"key":"1721_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejpb.2020.02.010","volume":"149","author":"KY Wan","year":"2020","unstructured":"Wan KY, et al. Converting nanosuspension into inhalable and redispersible nanoparticles by combined in-situ thermal gelation and spray drying. Eur J Pharm Biopharm. 2020;149:238\u201347.","journal-title":"Eur J Pharm Biopharm"},{"key":"1721_CR35","doi-asserted-by":"publisher","first-page":"121704","DOI":"10.1016\/j.ijpharm.2022.121704","volume":"619","author":"HC Seow","year":"2022","unstructured":"Seow HC, et al. Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. Int J Pharm. 2022;619:121704.","journal-title":"Int J Pharm"},{"key":"1721_CR36","doi-asserted-by":"crossref","unstructured":"Wong SN et al. Development of favipiravir dry powders for intranasal delivery: an integrated cocrystal and particle engineering approach via spray freeze drying. Int J Pharm, 2024. 653.","DOI":"10.1016\/j.ijpharm.2024.123896"},{"key":"1721_CR37","doi-asserted-by":"publisher","first-page":"121720","DOI":"10.1016\/j.ijpharm.2022.121720","volume":"620","author":"S Cunha","year":"2022","unstructured":"Cunha S, et al. Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. Int J Pharm. 2022;620:121720.","journal-title":"Int J Pharm"},{"issue":"5","key":"1721_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40005-023-00630-1","volume":"53","author":"P Henriques","year":"2023","unstructured":"Henriques P, et al. Amorphous nasal powder advanced performance: in vitro\/ex vivo studies and correlation with in vivo pharmacokinetics. J Pharm Investig. 2023;53(5):723\u201342.","journal-title":"J Pharm Investig"},{"key":"1721_CR39","doi-asserted-by":"publisher","first-page":"119341","DOI":"10.1016\/j.ijpharm.2020.119341","volume":"582","author":"JZ Chen","year":"2020","unstructured":"Chen JZ, et al. In vitro assessment of an idealized nose for nasal spray testing: comparison with regional deposition in realistic nasal replicas. Int J Pharm. 2020;582:119341.","journal-title":"Int J Pharm"},{"issue":"11","key":"1721_CR40","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1007\/s11095-022-03388-7","volume":"39","author":"JZ Chen","year":"2022","unstructured":"Chen JZ, Finlay WH, Martin A. Vitro Regional Deposition of Nasal Sprays in an Idealized Nasal Inlet: comparison with in Vivo Gamma Scintigraphy. Pharm Res. 2022;39(11):3021\u20138.","journal-title":"Pharm Res"},{"key":"1721_CR41","doi-asserted-by":"publisher","first-page":"123877","DOI":"10.1016\/j.ijpharm.2024.123877","volume":"653","author":"HW Chan","year":"2024","unstructured":"Chan HW, et al. Inhalable paclitaxel nanoagglomerate dry powders for lung cancer chemotherapy: design of experiments-guided development, characterization and in vitro evaluation. Int J Pharm. 2024;653:123877.","journal-title":"Int J Pharm"},{"key":"1721_CR42","doi-asserted-by":"crossref","unstructured":"Weng J, Tong HHY, Chow SF. In Vitro Release Study of the Polymeric Drug nanoparticles: Development and Validation of a Novel Method. Pharmaceutics, 2020. 12(8).","DOI":"10.3390\/pharmaceutics12080732"},{"issue":"3","key":"1721_CR43","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/pharmaceutics13030385","volume":"13","author":"M Trenkel","year":"2021","unstructured":"Trenkel M, Scherlie\u00df R. Nasal powder formulations: In-Vitro Characterisation of the impact of powders on nasal Residence Time and sensory effects. Pharmaceutics. 2021;13(3):385.","journal-title":"Pharmaceutics"},{"key":"1721_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.brainresbull.2020.12.023","volume":"168","author":"Z Qiu","year":"2021","unstructured":"Qiu Z, et al. Angiopoietin-like 4 promotes angiogenesis and neurogenesis in a mouse model of acute ischemic stroke. Brain Res Bull. 2021;168:156\u201364.","journal-title":"Brain Res Bull"},{"key":"1721_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jare.2022.11.007","volume":"51","author":"CK Tsang","year":"2023","unstructured":"Tsang CK, et al. Maf1 is an intrinsic suppressor against spontaneous neural repair and functional recovery after ischemic stroke. J Adv Res. 2023;51:73\u201390.","journal-title":"J Adv Res"},{"issue":"1","key":"1721_CR46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1080\/10717544.2022.2064564","volume":"29","author":"X Li","year":"2022","unstructured":"Li X, et al. Preparation of baicalin-loaded ligand-modified nanoparticles for nose-to-brain delivery for neuroprotection in cerebral ischemia. Drug Deliv. 2022;29(1):1282\u201398.","journal-title":"Drug Deliv"},{"key":"1721_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neulet.2016.05.058","volume":"627","author":"Y Wu","year":"2016","unstructured":"Wu Y, et al. An apoe-derived mimic peptide, COG1410, alleviates early brain injury via reducing apoptosis and neuroinflammation in a mouse model of subarachnoid hemorrhage. Neurosci Lett. 2016;627:92\u20139.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1721_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/01.STR.20.1.84","volume":"20","author":"EZ Longa","year":"1989","unstructured":"Longa EZ, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84\u201391.","journal-title":"Stroke"},{"key":"1721_CR49","doi-asserted-by":"crossref","unstructured":"Mu Q et al. Neutrophil targeting platform reduces Neutrophil Extracellular traps for Improved Traumatic Brain Injury and Stroke Theranostics. Adv Sci (Weinh), 2024: p. e2308719.","DOI":"10.1002\/advs.202308719"},{"key":"1721_CR50","doi-asserted-by":"publisher","first-page":"104845","DOI":"10.1016\/j.ebiom.2023.104845","volume":"97","author":"R Liu","year":"2023","unstructured":"Liu R, et al. Plasma metabolomic profiling of patients with transient ischemic attack reveals positive role of neutrophils in ischemic tolerance. EBioMedicine. 2023;97:104845.","journal-title":"EBioMedicine"},{"key":"1721_CR51","first-page":"196","volume":"29","author":"Y Wu","year":"2023","unstructured":"Wu Y, et al. FUS-mediated HypEVs: neuroprotective effects against ischemic stroke. Bioact Mater. 2023;29:196\u2013213.","journal-title":"Bioact Mater"},{"key":"1721_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijpharm.2019.05.032","volume":"565","author":"B Chatterjee","year":"2019","unstructured":"Chatterjee B, et al. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm. 2019;565:258\u201368.","journal-title":"Int J Pharm"},{"key":"1721_CR53","doi-asserted-by":"publisher","first-page":"102377","DOI":"10.1016\/j.jddst.2021.102377","volume":"63","author":"JB Prajapati","year":"2021","unstructured":"Prajapati JB, Patel GC. Nose to brain delivery of Rotigotine loaded solid lipid nanoparticles: quality by design based optimization and characterization. J Drug Deliv Sci Technol. 2021;63:102377.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"1721_CR54","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1039\/D0NA01051K","volume":"3","author":"Z Whiteley","year":"2021","unstructured":"Whiteley Z, et al. Microfluidic synthesis of protein-loaded nanogels in a coaxial flow reactor using a design of experiments approach. Nanoscale Adv. 2021;3(7):2039\u201355.","journal-title":"Nanoscale Adv"},{"key":"1721_CR55","doi-asserted-by":"publisher","first-page":"213074","DOI":"10.1016\/j.bioadv.2022.213074","volume":"140","author":"J Weng","year":"2022","unstructured":"Weng J, et al. Mediating bio-fate of polymeric cholecalciferol nanoparticles through rational size control. Biomater Adv. 2022;140:213074.","journal-title":"Biomater Adv"},{"key":"1721_CR56","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/978-1-4612-4380-9_23","volume-title":"Breakthroughs in statistics: methodology and distribution","author":"GEP Box","year":"1992","unstructured":"Box GEP, Wilson KB. On the experimental attainment of Optimum conditions. Breakthroughs in statistics: methodology and distribution. New York: New York, NY: Springer; 1992. pp. 270\u2013310. S. Kotz and N.L. Johnson, Editors."},{"issue":"2","key":"1721_CR57","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ejpb.2014.07.004","volume":"88","author":"SF Chow","year":"2014","unstructured":"Chow SF, Sun CC, Chow AH. Assessment of the relative performance of a confined impinging jets mixer and a multi-inlet vortex mixer for curcumin nanoparticle production. Eur J Pharm Biopharm. 2014;88(2):462\u201371.","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"1721_CR58","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0169-409X(02)00161-8","volume":"54","author":"AJ Hirsh","year":"2002","unstructured":"Hirsh AJ. Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev. 2002;54(11):1445\u201362.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1721_CR59","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/10717544.2018.1428242","volume":"25","author":"A Giuliani","year":"2018","unstructured":"Giuliani A, et al. In vivo nose-to-brain delivery of the hydrophilic antiviral Ribavirin by microparticle agglomerates. Drug Deliv. 2018;25(1):376\u201387.","journal-title":"Drug Deliv"},{"key":"1721_CR60","doi-asserted-by":"crossref","unstructured":"Boyuklieva R, Pilicheva B. Micro- and Nanosized carriers for nose-to-Brain Drug Delivery in Neurodegenerative disorders. Biomedicines, 2022. 10(7).","DOI":"10.3390\/biomedicines10071706"},{"key":"1721_CR61","doi-asserted-by":"crossref","unstructured":"Maaz A, Blagbrough IS, De Bank PA. In Vitro Evaluation of Nasal Aerosol Depositions: an insight for direct nose to Brain Drug Delivery. Pharmaceutics, 2021. 13(7).","DOI":"10.3390\/pharmaceutics13071079"},{"issue":"3","key":"1721_CR62","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1208\/s12249-014-0092-0","volume":"15","author":"YS Cheng","year":"2014","unstructured":"Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech. 2014;15(3):630\u201340.","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"1721_CR63","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.xphs.2023.07.002","volume":"112","author":"HW Chan","year":"2023","unstructured":"Chan HW, et al. Role of particle size in Translational Research of Nanomedicines for successful drug delivery: discrepancies and inadequacies. J Pharm Sci. 2023;112(9):2371\u201384.","journal-title":"J Pharm Sci"},{"key":"1721_CR64","doi-asserted-by":"publisher","unstructured":"Almansour K, et al. Particle Engineering by Nano Spray Drying: optimization of process parameters with hydroethanolic versus aqueous solutions. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14040800.","DOI":"10.3390\/pharmaceutics14040800"},{"key":"1721_CR65","first-page":"112324","volume":"128","author":"SK Shukla","year":"2021","unstructured":"Shukla SK, et al. Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs. Biomater Adv. 2021;128:112324.","journal-title":"Biomater Adv"},{"issue":"1","key":"1721_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/cr030698+","volume":"104","author":"M-C Daniel","year":"2004","unstructured":"Daniel M-C, Astruc D. Gold nanoparticles: Assembly, Supramolecular Chemistry, Quantum-size-related properties, and Applications toward Biology, Catalysis, and Nanotechnology. Chem Rev. 2004;104(1):293\u2013346.","journal-title":"Chem Rev"},{"key":"1721_CR67","doi-asserted-by":"crossref","unstructured":"G\u00e4nger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a Review on Architecture, Physico-Chemical characteristics and Mucociliary Clearance of the nasal olfactory mucosa. Pharmaceutics, 2018. 10(3).","DOI":"10.3390\/pharmaceutics10030116"},{"key":"1721_CR68","doi-asserted-by":"publisher","first-page":"924501","DOI":"10.3389\/fmedt.2022.924501","volume":"4","author":"C Rigaut","year":"2022","unstructured":"Rigaut C, et al. Instillation of a dry powder in nasal casts: parameters influencing the olfactory deposition with uni- and bi-directional devices. Front Med Technol. 2022;4:924501.","journal-title":"Front Med Technol"},{"key":"1721_CR69","doi-asserted-by":"crossref","unstructured":"Ni\u017ei\u0107 Nodilo L et al. A dry powder platform for nose-to-brain delivery of Dexamethasone: Formulation Development and nasal deposition studies. Pharmaceutics, 2021. 13(6).","DOI":"10.3390\/pharmaceutics13060795"},{"key":"1721_CR70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","volume":"128","author":"V Bourganis","year":"2018","unstructured":"Bourganis V, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337\u201362.","journal-title":"Eur J Pharm Biopharm"},{"key":"1721_CR71","doi-asserted-by":"crossref","unstructured":"Bahadur S et al. Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders. Pharmaceutics, 2020. 12(12).","DOI":"10.3390\/pharmaceutics12121230"},{"key":"1721_CR72","doi-asserted-by":"crossref","unstructured":"Sousa F, Castro P. 3.4 - Cell-based in vitro models for nasal permeability studies, in Concepts and Models for Drug Permeability Studies, B. Sarmento, Editor. 2016, Woodhead Publishing. pp. 83\u2013100.","DOI":"10.1016\/B978-0-08-100094-6.00006-7"},{"issue":"1","key":"1721_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11596550-000000000-00000","volume":"51","author":"OJ David","year":"2012","unstructured":"David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012;51(1):15\u201328.","journal-title":"Clin Pharmacokinet"},{"key":"1721_CR74","doi-asserted-by":"crossref","unstructured":"Candadai AA et al. Neuroprotective effects of Fingolimod in a Cellular Model of Optic Neuritis. Cells, 2021. 10(11).","DOI":"10.3390\/cells10112938"},{"key":"1721_CR75","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbr.2017.07.039","volume":"352","author":"MG Balkaya","year":"2018","unstructured":"Balkaya MG, et al. Behavioral outcome measures to improve experimental stroke research. Behav Brain Res. 2018;352:161\u201371.","journal-title":"Behav Brain Res"},{"key":"1721_CR76","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3389\/fnins.2020.00842","volume":"14","author":"W Li","year":"2020","unstructured":"Li W, et al. Fingolimod inhibits inflammation but exacerbates brain edema in the Acute Phases of Cerebral Ischemia in Diabetic mice. Front Neurosci. 2020;14:842.","journal-title":"Front Neurosci"},{"issue":"2","key":"1721_CR77","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1161\/STROKEAHA.109.568899","volume":"41","author":"Y Hasegawa","year":"2010","unstructured":"Hasegawa Y, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41(2):368\u201374.","journal-title":"Stroke"},{"issue":"2","key":"1721_CR78","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1352458515587753","volume":"22","author":"V Racca","year":"2016","unstructured":"Racca V, et al. Fingolimod effects on left ventricular function in multiple sclerosis. Mult Scler. 2016;22(2):201\u201311.","journal-title":"Mult Scler"},{"issue":"1","key":"1721_CR79","first-page":"1","volume":"10","author":"MC Veronesi","year":"2020","unstructured":"Veronesi MC, et al. Imaging of intranasal drug delivery to the brain. Am J Nucl Med Mol Imaging. 2020;10(1):1\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4 Pt 1","key":"1721_CR80","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/0192623391019004-102","volume":"19","author":"JR Harkema","year":"1991","unstructured":"Harkema JR. Comparative aspects of nasal airway anatomy: relevance to inhalation toxicology. Toxicol Pathol. 1991;19(4 Pt 1):321\u201336.","journal-title":"Toxicol Pathol"},{"key":"1721_CR81","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jconrel.2023.06.005","volume":"359","author":"K Sasaki","year":"2023","unstructured":"Sasaki K, et al. Effective nose-to-brain drug delivery using a combination system targeting the olfactory region in monkeys. J Control Release. 2023;359:384\u201399.","journal-title":"J Control Release"},{"key":"1721_CR82","doi-asserted-by":"crossref","unstructured":"Belgamwar VS, et al. 23 - quantitative and qualitative analysis of direct nose-to-brain drug delivery. Direct nose-to-Brain Drug Delivery. Academic; 2021. pp. 459\u201381. C.V. Pardeshi and E.B. Souto, Editors.","DOI":"10.1016\/B978-0-12-822522-6.00027-8"},{"key":"1721_CR83","doi-asserted-by":"crossref","unstructured":"Paget G, Barnes J. Toxicity tests. Evaluation of drug activities: pharmacometrics, 1964. 1: pp. 135\u2013\u200965.","DOI":"10.1016\/B978-1-4832-2845-7.50012-8"},{"issue":"3","key":"1721_CR84","first-page":"e14097","volume":"13","author":"EK Edzie","year":"2021","unstructured":"Edzie EK, et al. Evaluation of the anatomical locations of stroke events from computed Tomography scan examinations in a Tertiary Facility in Ghana. Cureus. 2021;13(3):e14097.","journal-title":"Cureus"},{"issue":"4","key":"1721_CR85","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"L-A Keller","year":"2022","unstructured":"Keller L-A, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022;12(4):735\u201357.","journal-title":"Drug Deliv Transl Res"},{"key":"1721_CR86","unstructured":"Trevino JT et al. Non-invasive strategies for nose-to-Brain Drug Delivery. J Clin Trials, 2020. 10(7)."},{"issue":"3","key":"1721_CR87","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","volume":"35","author":"JJ Lochhead","year":"2015","unstructured":"Lochhead JJ, et al. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab. 2015;35(3):371\u201381.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1721_CR88","doi-asserted-by":"crossref","unstructured":"Patharapankal EJ, et al. Nose-to-brain (N2B) delivery: an Alternative Route for the Delivery of Biologics in the management and treatment of Central Nervous System disorders. Pharmaceutics. 2024;16.","DOI":"10.3390\/pharmaceutics16010066"},{"issue":"2","key":"1721_CR89","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/17425247.2020.1714589","volume":"17","author":"B Forbes","year":"2020","unstructured":"Forbes B, et al. A consensus research agenda for optimising nasal drug delivery. Expert Opin Drug Deliv. 2020;17(2):127\u201332.","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01721-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01721-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01721-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T09:04:55Z","timestamp":1745831095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01721-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01721-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4715108\/v1","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"30 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies followed the ethical policies and guidelines recommended by ARRIVE (Animal Research: Reporting of In Vivo Experiments) and National Research Council\u2019s Guide for the Care and Use of Laboratory Animals and were approved by the Ethics Committee of the Animal Experimentation of Jinan University (Approval No.: 20230901-0012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}